Haemonetics approves restructuring $20M charges; targets $30M annual savings

HAEMONETICS CORP

Board approved market and regional alignment initiative in May 2025.
Expected aggregate restructuring charges of ~$20M, half severance, half other exit costs.
Savings of ~$30M annually expected by end fiscal 2027.
Q4 and FY 2025 earnings press released issued; no specific figures available in filing.
Charges will be cash outlays; initiative to continue through fiscal 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.